Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL)

Yasmin Karimi; Catherine Thieblemont; Herve Ghesquieres; Chan Y. Cheah; Michael Roost Clausen; David Cunningham; Wojciech Jurczak; Kim M. Linton; Martin Hutchings; Tycel Jovelle Phillips; Umar Farooq; Won Seog Kim; Minh H. Dinh; Jagannath Ghosh; Rajash Pallai; Monica Wielgos-Bonvallet; Christian Eskelund; Pieternella Lugtenburg; Julie Vose

doi:10.1200/JCO.2024.42.16_suppl.7039

Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL)

Yasmin Karimi, Catherine Thieblemont, Herve Ghesquieres, Chan Y. Cheah, Michael Roost Clausen, David Cunningham, Wojciech Jurczak, Kim M. Linton, Martin Hutchings, Tycel Jovelle Phillips, Umar Farooq, Won Seog Kim, Minh H. Dinh, Jagannath Ghosh, Rajash Pallai, Monica Wielgos-Bonvallet, Christian Eskelund, Pieternella Lugtenburg, Julie Vose

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	42
Issue number	16
Early online date	29 May 2024
DOIs	https://doi.org/10.1200/JCO.2024.42.16_suppl.7039
Publication status	Published - 1 Jun 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2024.42.16_suppl.7039

Cite this

Karimi, Y., Thieblemont, C., Ghesquieres, H., Cheah, C. Y., Clausen, M. R., Cunningham, D., Jurczak, W., Linton, K. M., Hutchings, M., Phillips, T. J., Farooq, U., Kim, W. S., Dinh, M. H., Ghosh, J., Pallai, R., Wielgos-Bonvallet, M., Eskelund, C., Lugtenburg, P., & Vose, J. (2024). Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Journal of Clinical Oncology, 42(16). https://doi.org/10.1200/JCO.2024.42.16_suppl.7039

@article{cb9db87f65df4d23b2b273913cdda9e8,

title = "Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL)",

author = "Yasmin Karimi and Catherine Thieblemont and Herve Ghesquieres and Cheah, {Chan Y.} and Clausen, {Michael Roost} and David Cunningham and Wojciech Jurczak and Linton, {Kim M.} and Martin Hutchings and Phillips, {Tycel Jovelle} and Umar Farooq and Kim, {Won Seog} and Dinh, {Minh H.} and Jagannath Ghosh and Rajash Pallai and Monica Wielgos-Bonvallet and Christian Eskelund and Pieternella Lugtenburg and Julie Vose",

year = "2024",

month = jun,

day = "1",

doi = "10.1200/JCO.2024.42.16_suppl.7039",

language = "English",

volume = "42",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "16",

}

Karimi, Y, Thieblemont, C, Ghesquieres, H, Cheah, CY, Clausen, MR, Cunningham, D, Jurczak, W, Linton, KM, Hutchings, M, Phillips, TJ, Farooq, U, Kim, WS, Dinh, MH, Ghosh, J, Pallai, R, Wielgos-Bonvallet, M, Eskelund, C, Lugtenburg, P & Vose, J 2024, 'Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL)', Journal of Clinical Oncology, vol. 42, no. 16. https://doi.org/10.1200/JCO.2024.42.16_suppl.7039

Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). / Karimi, Yasmin; Thieblemont, Catherine; Ghesquieres, Herve et al.
In: Journal of Clinical Oncology, Vol. 42, No. 16, 01.06.2024.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial

T2 - Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL)

AU - Karimi, Yasmin

AU - Thieblemont, Catherine

AU - Ghesquieres, Herve

AU - Cheah, Chan Y.

AU - Clausen, Michael Roost

AU - Cunningham, David

AU - Jurczak, Wojciech

AU - Linton, Kim M.

AU - Hutchings, Martin

AU - Phillips, Tycel Jovelle

AU - Farooq, Umar

AU - Kim, Won Seog

AU - Dinh, Minh H.

AU - Ghosh, Jagannath

AU - Pallai, Rajash

AU - Wielgos-Bonvallet, Monica

AU - Eskelund, Christian

AU - Lugtenburg, Pieternella

AU - Vose, Julie

PY - 2024/6/1

Y1 - 2024/6/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:001275557401688&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1200/JCO.2024.42.16_suppl.7039

DO - 10.1200/JCO.2024.42.16_suppl.7039

M3 - Meeting Abstract

SN - 0732-183X

VL - 42

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

ER -

Karimi Y, Thieblemont C, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D et al. Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Journal of Clinical Oncology. 2024 Jun 1;42(16). Epub 2024 May 29. doi: 10.1200/JCO.2024.42.16_suppl.7039

Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL)

UN SDGs

Access to Document

Other files and links

Cite this